Cancer
Malignant Colon Neoplasm
CI-CAN-00007995Explore in graph →
Top-level225 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007995Explore in graph →
Clinical trials
1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (139)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06746012 | Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers | recruiting | N/A | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 |
| clinicaltrials |
| NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)(FIRST-K) | not yet recruiting | Phase 2 | 88 | Korea University Anam HospitalOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05142033 | Avera Cancer Sequencing and Analytics Protocol (ASAP)(ASAP) | recruiting | — | 25,000 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07494201 | MIMICC Study in Patients With Colorectal Cancer(MIMICC) | recruiting | N/A | 2,500 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06698289 | Preoperative Sarcopenia and Surgical Outcomes in Colorectal Cancer Patients | completed | — | 70 | Mersin UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer(SCOTI) | recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06802991 | Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0) | recruiting | N/A | 60 | Copenhagen University Hospital at HerlevOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04668872 | Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation | recruiting | — | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma(TRIUNITE-08) | recruiting | Phase 2 | 106 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06191185 | IMProving Adherence to Colonoscopy Through Teams and Technology(IMPACTT) | enrolling by invitation | N/A | 2,000 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03446157 | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06281925 | Cryotherapy & Oxaliplatin | suspended | N/A | 40 | NYU Langone HealthOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07432399 | Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)(PILDI) | recruiting | Phase 2 | 100 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03026140 | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer(NICHE) | recruiting | Phase 2 | 353 | The Netherlands Cancer InstituteOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05672108 | Phase II Trial of Lung Chemoemobolization | recruiting | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02738359 | Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening(FAMCAP) | completed | — | 84 | Hôpital Edouard HerriotOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07427901 | Quality Of Life In Colorectal Cancer Survivors | recruiting | N/A | 368 | Institute of Oncology LjubljanaOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07428239 | Pilot Study of Individualized Comprehensive Rehabilitation in Patients With Colorectal Cancer | completed | N/A | 150 | Institute of Oncology LjubljanaOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03523546 | Oncology Episode Payment Model in Hawaii | active not recruiting | N/A | 7 | University of PennsylvaniaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | terminated | Phase 2 | 76 | Inspirna, Inc.INDUSTRY | 3 | Feb 20, 2026 | clinicaltrials |
| NCT07409844 | Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer(RESET C2) | not yet recruiting | Phase 2 | 152 | Ismail GögenurOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07413146 | Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial | not yet recruiting | N/A | 100 | Sun Yat-sen UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06830239 | Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer(Superhero) | recruiting | Phase 2 | 10 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07405931 | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients | recruiting | N/A | 414 | Ulsan University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05036109 | DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease | completed | N/A | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03712943 | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | completed | Phase 1 | 52 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05421702 | Comparison Between Results of 2 Laparoscopic Surgical Procedures in Operable Colon Cancer Cases in Upper Egypt | completed | N/A | 150 | Sohag UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02724202 | Curcumin in Combination With 5FU for Colon Cancer | terminated | Early Phase 1 | 15 | Baylor Research InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04916990 | Improving Care for Rural Patients With Solid Tumors | recruiting | N/A | 320 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06923787 | Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study(PILDI) | recruiting | Phase 2 | 100 | Institute of Oncology LjubljanaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05062889 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients(ERASE-CRC) | suspended | Phase 2 | 477 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02448173 | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | not yet recruiting | Phase 3 | 550 | Vaccinogen IncINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer(T-REX) | completed | — | 3,647 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 7 | Jan 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials